Jessie F Fecteau

Learn More
In humans, up to 40% of peripheral B cells express CD27 and have hypermutated variable regions in their Ig genes. The CD27+ B cells are considered to be derived from germinal center following specific antigenic stimulation. Actually, somatic hypermutation in Ig genes and CD27 expression are hallmarks of memory B cells. However, the blood IgM+ IgD+ CD27+ B(More)
During secondary immune response, memory B lymphocytes proliferate and differentiate into Ig-secreting cells. In mice, the binding of CD40 by CD154 clearly enhances the activation and differentiation of memory B lymphocytes. In humans, the role of CD40-CD154 in the stimulation of memory B lymphocytes is not as obvious since in vitro studies reported(More)
In vitro CD40 stimulation of human B cells isolated from lymphoid organs is dominated by memory B cells undergoing faster proliferation and higher differentiation than naive B cells. In contrast, we previously reported that blood memory B cells mainly differentiate into immunoglobulin-secreting cells in response to CD40 stimulation. However, variations in(More)
High mobility group box protein 1 (HMGB1) acts as an endogenous danger molecule that is released from necrotic cells and activated macrophages. We have previously shown that peptide Hp91, whose sequence corresponds to an area within the B-Box domain of HMGB1, activates dendritic cells (DCs) and acts as an adjuvant in vivo. Here we investigated the(More)
(Supplementary Figure 2g). Flow cytomery analysis on fetal liver cells revealed that overall fetal hematopoiesis in Pten / mice was normal, except a skewed lymphoid/myeloid development at the progenitor level. There was no reduction in the hematopoietic stem cell-enriched lin sca-1þ c-kitþ population. However, there was an increased percentage of common(More)
elacytarabine CIV in the dose range 875--2000mg/m per day may allow more flexible administration and dosing than for ara-C. AUC values for both substances and the increased initial half-life of ara-C after elacytarabine administration (2.0 h versus 0.1 --0.2 h), indicate that treatment with elacytarabine provides plasma levels of both elacytarabine and(More)
  • 1